Crawling into bed to rest her painful left toe, Mel Gardener winced as she covered herself with a cotton sheet. Even the touch of this light fabric was excruciating.

Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882: San Diego Wednesday, March 19, 2025, 11:00 Hrs [IST] Arthrosi Therape ...

If you've ever been going about your day only to get hit with excruciating joint pain, it could be gout. While this type of ...

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...

Nephrologist Jason B. Rothschild, MD, recently joined Gayle Guyardo, the host of the globally syndicated health and wellness show Bloom, to discuss the often-overlooked ...

and dissolve tophi in gout and tophaceous gout patients, today announced the completion of enrollment for its pivotal global Phase 3 REDUCE 2 trial. "We would like to thank the gout community for ...

refractory gout is a persistence of clinical manifestations characterised by the inability to reduce the serum urate acid concentration below the target 6.0 mg/dL, increased MSU deposition and tophi ...

163.com Our cohort of patients with juvenile gout (age of onset ≤18 years) consisted of 107 males and 4 females. All patients met the 2015 ACR/EULAR Criteria for gout. The mean age of symptom onset ...

Gout can affect other joints. It may also cause “tophi” to develop (hard swellings around joints and the ears). Gout typically occurs in bouts or attacks, before settling with treatment and becoming ...

gout_codes_icd10_str = 'M10, M10.0, M10.00, M10.01, M10.011, M10.012, M10.019, M10.02, M10.021, M10.022, M10.029, M10.03, M10.031, M10.032, M10.039, M10.04, M10.041 ...